Can-Fite BioPharma Ltd.CANFNYSE
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
-3.78%
↓ 149% below average
Average (9y)
7.64%
Historical baseline
Range
High:80.67%
Low:-22.93%
CAGR
-7.1%
Structural decline
| Period | Value |
|---|---|
| 2024 | -3.78% |
| 2023 | -22.93% |
| 2022 | -21.19% |
| 2021 | -17.58% |
| 2020 | 8.88% |
| 2019 | 80.67% |
| 2018 | 15.24% |
| 2017 | -13.27% |
| 2016 | 57.63% |
| 2015 | -7.32% |